JNJ 67484703
Alternative Names: JNJ-4703; JNJ-67484703Latest Information Update: 11 Apr 2024
At a glance
- Originator Janssen Research & Development
- Class Anti-inflammatories; Antibodies; Antirheumatics; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Rheumatoid arthritis; Sjogren's syndrome; Ulcerative colitis
Most Recent Events
- 31 Mar 2024 Janssen Research and Development completes a phase II clinical trial in Sjogren's syndrome, Ulcerative colitis (Treatment experienced) and Rheumatoid arthritis (Treatment experienced) in United Kingdom (SC, Injection) (ISRCTN31164692) (EudraCT2021-005998-13)
- 18 May 2023 Janssen Research & Development completes a phase I trial in Rheumatoid arthritis (Treatment-experienced) in Ukraine, Georgia, USA (Parenteral) (NCT04985812)
- 02 Feb 2023 Phase-II clinical trials in Atopic dermatitis (In adults, In the elderly) in Germany (SC) (EudraCT2022-001528-14)